Q-Linea — Proxy Solicitation & Information Statement 2026

Mar 11, 2026

Q-LINEA

The nomination committee's proposals to Q-linea's annual general meeting 2026

The nomination committee of Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) has submitted its proposals to Q-linea’s annual general meeting 2026. The nomination committee proposes that Öystein Engebretsen and Kari Krogstad are elected as a new board members and that Johan Bygge, Mario Gualano, Erika Kjellberg Eriksson, Jonas Jarvius and Sebastian Backlund are re-elected as board members. Karin Fischer has declined re-election. The nomination committee proposes that Johan Bygge is re-elected as chairman of the board and that Mario Gualano is re-elected as vice chairman of the board.

Election of chairman, vice chairman and members of the board of directors

The nomination committee proposes that Öystein Engebretsen and Kari Krogstad are elected as new board members and that Johan Bygge, Mario Gualano, Erika Kjellberg Eriksson, Jonas Jarvius and Sebastian Backlund are re-elected as board members. Karin Fischer has declined re-election. The nomination committee proposes that Johan Bygge is re-elected as chairman of the board and that Mario Gualano is re-elected as vice chairman of the board.

Öystein Engebretsen is Investment manager at Investment AB Öresund with a long experience from the finance- and investment sector as well as an extensive board level experience.

Kari Krogstad is the CEO of Medistim and has more than 30 years of experience from the biomedical industry, from commercial leadership roles within the pharma, biotech and medtech sectors.

The board members' independence pursuant to the Swedish Corporate Governance Code

The nomination committee assesses that all of the proposed board members are independent of the company and its senior management and that three of the proposed board members (Johan Bygge, Mario Gualano and Jonas Jarvius) are independent of Q-linea's major shareholders.

Election of auditor

The nomination committee proposes, in accordance with the risk- and audit committee's recommendation, that Öhrlings PricewaterhouseCoopers AB is re-elected as auditor for the period until the close of the next annual general meeting.

Fees to the board of directors and the auditor

The nomination committee proposes that the fee to the chairman of the board shall be SEK 500,000 (SEK 500,000), that the fee to the vice chairman of the board shall be SEK 375,000 (SEK 375,000) and that the individual fee payable to the other non-employed board members elected by the annual general meeting shall be SEK 250,000 (SEK 250,000).

In addition, the nomination committee proposes that the fees to members of the committees of the board shall be paid as follows. An individual annual fee of SEK 90,000 (SEK 90,000) for the chairman of the audit committee and SEK 45,000 (SEK 45,000) for each of the two other members of the audit committee as well as SEK 40,000 (SEK 40,000) for the chairman of the remuneration committee and SEK 20,000 (SEK 20,000) for the two other members of the remuneration committee.

Q-linea • Dag Hammarskjölds väg 52A • SE-752 37 Uppsala

---

Q-LINEA

The nomination committee proposes that the auditor fees are paid against approved account.

The composition of the nomination committee and the committee's complete proposals

The nomination committee for the annual general meeting 2026 consists of Öystein Engebretsen (chairman), Erika Kjellberg Eriksson, Ulf Landegren and Johan Bygge.

The nomination committee's complete proposals, including its reasoned statement and information on the proposed board members, will be available on Q-linea's website, www.qlinea.com, not later than three weeks prior to the annual general meeting.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company's core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.

Q-linea's flagship technology, ASTar®, is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea is listed on Nasdaq Stockholm.

Attachments

The nomination committee's proposals to Q-linea's annual general meeting 2026

Q-linea • Dag Hammarskjölds väg 52A • SE-752 37 Uppsala